Zhengzhou Kodia Biotechnology Co., Ltd.

1 · Legal Entity and Registered Office

2 · Vision, Mission and Core Values

Corporate Vision

To emerge as a new driving force in China's molecular diagnostics industry, and to serve as a pathfinder in molecular pathology and diagnostics.

Corporate Mission

To make diagnostic testing simpler and more precise.

Core Values

People-oriented; united by integrity; resilient in execution; dedicated to excellence; founded on trustworthiness; committed to honest conduct.

Corporate Creed

Govern oneself before governing others; perfect oneself in order to perfect one's work. (正己正人 · 成己成物)

3 · Proprietary Technology Platform — QuantiMAT

Kodia has developed the QuantiMAT platform, a proprietary, patent-protected technology for molecular nucleic-acid biomarker detection. The platform underpins Kodia's current product pipeline and is the basis of the company's lead cervical-cancer screening assay.

[Patent numbers, underlying chemistry, and a non-confidential technical summary will be provided under mutual non-disclosure agreement upon request by N-Health Thailand.]

4 · Lead Product — HPV E6/E7 mRNA Detection Kit

4.1 Product Description

Kodia's inaugural commercial product is the HPV E6/E7 mRNA Detection Kit, an in vitro diagnostic assay for the qualitative detection of E6/E7 messenger-RNA transcripts from high-risk human papillomavirus (HR-HPV) genotypes in cervical specimens.

4.2 Regulatory Recognition in P.R. China

The kit is the first domestically developed IVD product in the People's Republic of China indicated for the assessment of cervical carcinogenesis risk. It has been recognized by the Ministry of Science and Technology of the People's Republic of China (MOST) as a "Domestically Innovative" product and included in the national Innovative Medical Device Product Directory.

4.3 Clinical Adoption

The product has been deployed across several hundred hospitals and clinical laboratories in China and is in routine use as a tool for the assessment of cervical carcinogenesis risk.

4.4 Alignment with International OB-GYN Guidelines

The E6/E7 mRNA biomarker is consistent with the biological rationale recognised by:

• WHO — Recommendations on Screening and Treatment of Pre-cancer Lesions for Cervical Cancer (2021), which identify high-risk HPV molecular testing as the preferred primary screening modality;
• FIGO staging principles for cervical cancer;
• ACOG guidance supporting mRNA-based triage where analytically and clinically validated;
• NCCN and ESGO frameworks that recognise oncogene expression markers as risk-stratification tools for high-grade cervical intraepithelial neoplasia (CIN2+).

[A full technical dossier — analytical sensitivity/specificity, clinical sensitivity/specificity, PPV, NPV with 95% confidence intervals, and peer-reviewed references — will be provided to N-Health Thailand upon execution of the evaluation framework.]

5 · Research and Development Capability

5.1 Scientific Team

Kodia's R&D team comprises approximately ten (10) doctoral-level scientists with training across medicine, oncology, molecular biology, chemistry, and mass spectrometry, combining domestic and international research experience.

5.2 In-house Technology Platforms

• QuantiMAT (proprietary)
• Immunohistochemistry (IHC)
• Fluorescence in situ Hybridization (FISH)
• Reverse Transcription Polymerase Chain Reaction (RT-PCR)
• Multiplex PCR

5.3 Therapeutic and Disease Focus

• Solid tumors
• Early-stage cancer screening
• Infectious diseases
• Women's and children's health

5.4 Scope of Activities

Discovery, analytical and clinical validation, development, and manufacturing of molecular nucleic-acid biomarkers across the disease areas listed above.

6 · Manufacturing and Quality Assurance

[To be supplied by Kodia:

• NMPA IVD Manufacturing License — number, scope, validity [ ]
• ISO 13485:2016 certificate — notified body, number, validity [ ]
• GMP compliance status [ ]
• Manufacturing site address and capacity [ ]

]

7 · Proposed Collaboration Framework with BDMS / N-Health Thailand

Consistent with the framework proposed by Dr. Narintara Boonjongcharoen, MD., Chief Executive Officer, BDMS Group 4, Kodia respectfully endorses the following collaboration structure:

1. Initial non-binding MOU. An initial, non-binding strategic Memorandum of Understanding between Kodia Biotechnology and Bangkok Hospital Chiang Mai (BCM), to establish goodwill and to facilitate subsequent technical evaluation.
2. N-Health Thailand to lead evaluation. N-Health Thailand to lead the comprehensive scientific, technical, regulatory, and commercial evaluation of Kodia's diagnostic technologies, with full cooperation and technical disclosure from Kodia.
3. Strategic partnership for Thailand market entry. Upon successful evaluation, a strategic partnership between N-Health Thailand and Kodia Biotechnology for research, analytical and clinical validation, Thai FDA regulatory approval, and market introduction in the Kingdom of Thailand — with potential expansion into the broader ASEAN and Southeast Asian markets.
4. Clinical research and validation participation. BCM and other BDMS hospitals to participate as clinical research and validation partners, subject to institutional ethics committee approval and applicable Thai regulatory requirements.

9 · Contact